NAPWA

Adrian Ogier gives the low-down on latest antiretroviralA medication or other substance which is active against retroviruses such as HIV. treatments. read more »

New data about IDX899, an experimental(Of a drug) Not licensed for use in humans, or as a treatment for a particular condition. Experimental drugs are studied in clinical trials to determine their safety and efficacy(Of a drug or treatment). The maximum ability of a drug or treatment to produce a result regardless of dosage. A drug passes efficacy trials if it is effective at the dose tested and against the illness for which it is prescribed. In the standard procedure, Phase II clinical trials gauge efficacy, and Phase III trials confirm it., and are sometimes made available via Special Access Schemes prior to their approval. next generation NNRTI, was presented at the International AIDS Conference, showing reduced viral loadA measurement of the quantity of HIV RNA in the blood. Viral load blood test results are expressed as the number of copies (of HIV) per milliliter of blood plasma. in test tube studies both in wild-type HIV and strains with NNRTI-resistanceHIV which has mutated and is less susceptible to the effects of one or more anti-HIV drugs is said to be resistantHIV which has mutated and is less susceptible to the effects of one or more anti-HIV drugs is said to be resistant.. mutations. read more »

A presentation at the International AIDS Conference looked at nanosuspension, a formulation of very small crystals which have been reduced to approximately twice the diameter of an HIV particle. read more »

Follow-up results from a Phase IIA smaller clinical trialA clinical trial is a research study to answer specific questions about vaccines or new therapies or new ways of using known treatments. Clinical trials are used to determine whether new drugs or treatments are both safe and effective. Carefully conducted clinical trials are the fastest and safest way to find treatments that work in people. Trials are in four phases: Phase I tests a new drug or treatment in a small group; Phase II expands the study to a larger group of people; Phase III expands the study to an even larger group of people; and Phase IV takes place after the drug or treatment has been licensed and marketed. designed to establish whether a drug is effective. Phase II studies are conducted to evaluate the effectiveness(Of a drug or treatment). The maximum ability of a drug or treatment to produce a result regardless of dosage. A drug passes efficacy trials if it is effective at the dose tested and against the illness for which it is prescribed. In the standard procedure, Phase II clinical trials gauge efficacy, and Phase III trials confirm it. of the drug for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks. If there is evidence that the drug is effective, a Phase IIIA large clinical trial designed to establish whether a drug is effective and safe enough for widespread use. Phase III studies include expanded controlled and uncontrolled trials after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug and provide and adequate basis for physician labeling. study is undertaken, with a larger number of participaants, to confirm this. study of rilpivirine (TMC-278), Tibotec’s experimental(Of a drug) Not licensed for use in humans, or as a treatment for a particular condition. Experimental drugs are studied in clinicalPertaining to or founded on observation and treatment of participants, as distinguished from theoretical or basic science. trials to determine their safety and efficacy, and are sometimes made available via Special Access Schemes prior to their approval. next generation NNRTI, indicate that when combined with Truvada or Combivir, rilpivirine has comparable results to the leading NNRTI, efavirenz. read more »

A possible new treatment for excessive abdominal fat associated with HIV-related lipodystrophy was presented at IAS 2008. read more »

An experimental(Of a drug) Not licensed for use in humans, or as a treatment for a particular condition. Experimental drugs are studied in clinical trials to determine their safety and efficacy, and are sometimes made available via Special Access Schemes prior to their approval. NNRTI, RDEA806, appeared to have strong antiviralA medication or substance which is active against one or more virusesA small infective organism which is incapable of reproducing outside a host cell.. May include anti-HIV drugs, but these are more accurately termed antiretroviralsA medication or other substance which is active against retroviruses such as HIV.. activity and a favourable safety profile in a Phase IIA smaller clinicalPertaining to or founded on observation and treatment of participants, as distinguished from theoretical or basic science. trial designed to establish whether a drug is effective. Phase II studies are conducted to evaluate the effectiveness(Of a drug or treatment). The maximum ability of a drug or treatment to produce a result regardless of dosage. A drug passes efficacy trials if it is effective at the dose tested and against the illness for which it is prescribed. In the standard procedure, Phase II clinical trials gauge efficacy, and Phase III trials confirm it. of the drug for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks. If there is evidence that the drug is effective, a Phase IIIA large clinical trial designed to establish whether a drug is effective and safe enough for widespread use. Phase III studies include expanded controlled and uncontrolled trials after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug and provide and adequate basis for physician labeling. study is undertaken, with a larger number of participaants, to confirm this. study presented at IAS 2008. read more »

With increasing numbers of people with HIV developing non-AIDS illnesses, physicians are debating whether to start treatment earlier than is currently recommended. read more »

In a disappointing finding from the REAL study, little difference was shown in visceral fat levels from those who shifted to atazanavir/ritonavir versus those remaining on their existing boosted protease inhibitorA type of anti-HIV drug that works by preventing the production of an enzyme, protease, that HIV needs to replicate.. read more »

People who adhere closely to a Mediterranean diet — comprising olive oil, grains, fruits, nuts, vegetables and fish and low in meat and dairy – may have a lower risk of developing diabetes[Diabetes mellitus[Diabetes mellitus] A disorder in which sugars in the diet cannot be metabolised into energy due to a lack of the enzyme insulin. Late-onset diabetes mellitus may be a long-term side effect of some anti-HIV drugs.] A disorder in which sugars in the diet cannot be metabolised into energy due to a lack of the enzyme insulin. Late-onset diabetes mellitus may be a long-term side effectAn unwanted effect caused by the administration of drugs. Onset may be sudden or develop over time. of some anti-HIV drugs. according to a recent study. read more »

A New Zealand company is working on an antiviralA medication or substance which is active against one or more virusesA small infective organism which is incapable of reproducing outside a host cell.. May include anti-HIV drugs, but these are more accurately termed antiretroviralsA medication or other substance which is active against retroviruses such as HIV.. agent that utilises the immune system to fight fluA highly contagious and relatively common viral infection of the respiratory system, transmitted by infected droplets of moisture which may be spread through coughing and sneezing. Most people with flu recover but some go on to develop secondary infections such as pneumoniaAn inflammation of the lung, usually caused by infection with bacteria or other microorganisms, in which the air sacs of the lung become filled with inflammatory cells which solidify and inhibit breathing. which may be fatal., hepatitis and HIV. read more »

An encouraging outcome of the DUET studies is that etravirine is effective against HIV mutations resistantHIV which has mutated and is less susceptible to the effects of one or more anti-HIV drugs is said to be resistant. to existing NNRTIs, efavirenz and nevirapine. read more »

The simple answer is ‘no’ according to Dr Brian Hughes, Infectious Diseases Physician and hepatitis specialist at John Hunter Hospital in Newcastle. read more »

A warning has been issued by Tibotec, the manufacturers of Prezista (darunavir) regarding the risk of developing drug- induced hepatitis while taking the treatment. read more »